WO2002079404A3 - Cytoskeleton-associated proteins - Google Patents

Cytoskeleton-associated proteins Download PDF

Info

Publication number
WO2002079404A3
WO2002079404A3 PCT/US2002/009288 US0209288W WO02079404A3 WO 2002079404 A3 WO2002079404 A3 WO 2002079404A3 US 0209288 W US0209288 W US 0209288W WO 02079404 A3 WO02079404 A3 WO 02079404A3
Authority
WO
WIPO (PCT)
Prior art keywords
csap
cytoskeleton
associated proteins
polynucleotides
agonists
Prior art date
Application number
PCT/US2002/009288
Other languages
French (fr)
Other versions
WO2002079404A2 (en
Inventor
April J A Hafalia
Tom Y Tang
Henry Yue
Farrah A Khan
Craig H Ison
Original Assignee
Incyte Genomics Inc
April J A Hafalia
Tom Y Tang
Henry Yue
Farrah A Khan
Craig H Ison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, April J A Hafalia, Tom Y Tang, Henry Yue, Farrah A Khan, Craig H Ison filed Critical Incyte Genomics Inc
Priority to US10/473,574 priority Critical patent/US20040116670A1/en
Priority to EP02757814A priority patent/EP1373306A4/en
Priority to JP2002578407A priority patent/JP2004533227A/en
Priority to AU2002306879A priority patent/AU2002306879A1/en
Priority to CA002441654A priority patent/CA2441654A1/en
Publication of WO2002079404A2 publication Critical patent/WO2002079404A2/en
Publication of WO2002079404A3 publication Critical patent/WO2002079404A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)

Abstract

The invention provides human cytoskeleton-associated proteins (CSAP) and polynucleotides which identify and encode CSAP. The invention also providing expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CSAP.
PCT/US2002/009288 2001-03-29 2002-03-25 Cytoskeleton-associated proteins WO2002079404A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/473,574 US20040116670A1 (en) 2002-03-25 2002-03-25 Cytoskeleton-associated proteins
EP02757814A EP1373306A4 (en) 2001-03-29 2002-03-25 Cytoskeletion-associated proteins
JP2002578407A JP2004533227A (en) 2001-03-29 2002-03-25 Cytoskeletal binding protein
AU2002306879A AU2002306879A1 (en) 2001-03-29 2002-03-25 Cytoskeleton-associated proteins
CA002441654A CA2441654A1 (en) 2001-03-29 2002-03-25 Cytoskeleton-associated proteins

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US28050801P 2001-03-29 2001-03-29
US60/280,508 2001-03-29
US28132301P 2001-04-03 2001-04-03
US60/281,323 2001-04-03
US28376901P 2001-04-13 2001-04-13
US60/283,769 2001-04-13
US28860901P 2001-05-04 2001-05-04
US60/288,609 2001-05-04
US29051801P 2001-05-10 2001-05-10
US60/290,518 2001-05-10
US29187001P 2001-05-18 2001-05-18
US60/291,870 2001-05-18
US29445101P 2001-05-29 2001-05-29
US60/294,451 2001-05-29

Publications (2)

Publication Number Publication Date
WO2002079404A2 WO2002079404A2 (en) 2002-10-10
WO2002079404A3 true WO2002079404A3 (en) 2003-03-20

Family

ID=27569565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009288 WO2002079404A2 (en) 2001-03-29 2002-03-25 Cytoskeleton-associated proteins

Country Status (5)

Country Link
EP (1) EP1373306A4 (en)
JP (1) JP2004533227A (en)
AU (1) AU2002306879A1 (en)
CA (1) CA2441654A1 (en)
WO (1) WO2002079404A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1402031A2 (en) 2001-06-21 2004-03-31 Isis Innovation Limited Atopy
AU2003228872A1 (en) * 2002-05-10 2003-11-11 Incyte Corporation Cell adhesion and extracellular matrix proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017355A2 (en) * 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
EP1171585A1 (en) * 1999-03-23 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] SATO ET AL.: "The genomic organization of type I keratin genes in mice", XP002958578, Database accession no. (Q9Z320) *
GENOMICS, vol. 56, no. 3, 1 May 1999 (1999-05-01), pages 303 - 309 *
See also references of EP1373306A4 *

Also Published As

Publication number Publication date
AU2002306879A1 (en) 2002-10-15
EP1373306A4 (en) 2005-07-20
EP1373306A2 (en) 2004-01-02
WO2002079404A2 (en) 2002-10-10
JP2004533227A (en) 2004-11-04
CA2441654A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
WO2001098468A3 (en) Proteases
WO2002063005A3 (en) Lipid-associated molecules
WO2002008396A3 (en) Human proteases
WO2002072794A3 (en) Immunoglobulin superfamily proteins
WO2002038744A3 (en) Proteases
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2001096546A3 (en) Protein phosphatases
WO2002026950A3 (en) Transferases
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2002086069A3 (en) Secreted proteins
WO2002070669A3 (en) Secreted proteins
WO2001071004A3 (en) Proteases
WO2002053719A3 (en) Cytoskeleton-associated proteins
WO2003062391A3 (en) Structural and cytoskeleton-associated proteins
WO2002024895A3 (en) Transcription factors and zinc finger proteins
WO2002024924A3 (en) Protein phosphatases
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2002020736A3 (en) Proteases
WO2001046443A3 (en) Proteases
WO2002042330A3 (en) Cystoskeleton-associated proteins
WO2003025542A3 (en) Immune response associated proteins
WO2002079441A3 (en) Secreted proteins
WO2002016587A3 (en) Microtubule-associated proteins and tubulins
WO2002079404A3 (en) Cytoskeleton-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002757814

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2441654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10473574

Country of ref document: US

Ref document number: 2002578407

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002757814

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002757814

Country of ref document: EP